MLYS — Mineralys Therapeutics, Inc.

Summary of Mineralys Therapeutics, Inc. Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Cash Position: As of March 31, 2026, Mineralys had cash, cash equivalents, and investments totaling $646.1 million, down from $656.6 million at the end of 2025. This is expected to fund operations into 2028.
• R&D Expenses: Decreased to $24.4 million from $37.9 million year-over-year, primarily due to the conclusion of the pivotal program for lorundrostat.
• G&A Expenses: Increased significantly to $21.0 million from $6.6 million year-over-year, driven by higher professional fees and personnel-related costs.
• Net Loss: Reported at $39.3 million, a slight improvement from $42.2 million in Q1 2025.
• Other Income: Increased to $6.0 million from $2.2 million, attributed to higher interest income from investments.

2. Strategic Updates and Business Highlights

• NDA Acceptance: The FDA accepted the New Drug Application (NDA) for lorundrostat, targeting a PDUFA date of December 22, 2026. This marks a significant milestone for the company.
• Clinical Data: The NDA is supported by positive results from five pivotal trials demonstrating lorundrostat's efficacy in reducing blood pressure and its tolerability across diverse patient populations.
• Market Strategy: Focus on launching lorundrostat for patients with uncontrolled or resistant hypertension, particularly those on multiple antihypertensive medications. The company is preparing for commercial success through early market access planning and payer engagement.
• Partnership Exploration: Mineralys is actively evaluating potential partnerships to enhance the value of lorundrostat and reach more patients.

3. Forward Guidance and Outlook

• The company remains optimistic about the upcoming PDUFA date and is focused on pre-commercial readiness activities. They believe their current financial position will support operations and clinical activities through 2028.
• The management expressed confidence in lorundrostat's potential to be included in prescribing guidelines due to its robust clinical data.

4. Bad News, Challenges, or Points of Concern

• Increased G&A Expenses: The significant rise in general and administrative expenses may raise concerns about operational efficiency and cost management.
• Competitive Landscape: The potential launch of AstraZeneca's baxdrostat could create competitive pressures, particularly regarding pricing and market access strategies.
• Partnership Delays: Ongoing discussions about partnerships have not yet yielded a definitive agreement, which may affect the company's strategic positioning and resource allocation.

5. Notable Q&A Insights

• Launch Strategy: If launching independently, the company plans to focus on maximizing value from lorundrostat while potentially limiting further R&D spending.
• Safety Profile: Management remains confident in the safety profile of lorundrostat, with ongoing data collection from the TRANSFORM HTN trial.
• Market Positioning: The company aims to position lorundrostat as a fourth-line treatment initially, with the potential to expand into third-line settings based on clinical data and payer feedback.
• Physician Engagement: There is a strong emphasis on engaging both cardiologists and nephrologists as key prescribers, leveraging the unique data from their clinical trials to drive adoption.
• Pricing Strategy: The company is cautious about pricing, indicating that they will assess AstraZeneca's pricing strategy before finalizing their own approach, with a focus on ensuring patient access.

Overall, Mineralys Therapeutics is at a pivotal moment with the NDA acceptance for lorundrostat, but faces challenges in managing expenses and navigating a competitive market landscape.